SMSbiotech

SMSbiotech is a clinical-stage regenerative medicine company developing a first-in-class Small Mobile Stem (SMS) cell therapy platform. Its lead COPD program has demonstrated early safety and encouraging efficacy signals in Phase 1b and is advancing toward U.S. clinical development and Phase 2. SMS cells, derived from adult human blood, are designed as an allogeneic, off-the-shelf therapy with the ability to engage key regenerative pathways. The platform is built to overcome limitations of existing cell therapies while enabling scalable, repeatable treatment approaches. The SMSbiotech platform technology will initiate a new era in regenerative medicine. This capability is supported by ISO-7 clean room infrastructure, enabling controlled, reproducible biomanufacturing. SMS cells' ability to proliferate extensively without loss of potency laid the ground for industrial-scale biomanufacturing, the basis for developing alternative and relevant disease-changing therapies.